Molecule intelOpportunity: Lower0Crowded market

Montelukast

225 brands · 182 companies · product forms

1 DRAP alert

Opportunity snapshot

Launch attractiveness
24
Market saturation
100
Price room
100
Regulatory risk
50
225
brands
182
companies
Rs 358.39
median price
82
price points
147.15x
price spread
90
confidence %

Who competes here

Top companies by brand count — fragmented market (no dominant player) · leader share 3%

Price room

Across observed sources and strengths
CheapestRs 19.96
MedianRs 358.39
Most expensiveRs 2,937.12
Spread147.15×
Sources: DRAP-official, DVAGO, Servaid

max/min price ratio 147.15x across 82 trusted points (Rs 19.96-2937.12). NOTE: mixes strengths (graph prices carry no strength), so treat as indicative.

Brands & products on the market

Sample of 12 live products for Montelukast — each links to its own medicine page.

Regulatory alerts

Safety exposurelatest 2025-10-16
RAPID ALERT – SPURIOUS/FALSIFIED (TABLET MYTEKA 10 mg)

Why this score

Launch attractiveness

40% supply-gap(0) + 25% price-variation(100) + 20% low-competition(0) + 15% supply-disruption(0), damped by confidence(90). Higher = more attractive, less crowded opportunity.

Market saturation

182 canonical companies and 225 brands compete (saturation pegged at 30 companies / 150 brands).

Price room

max/min price ratio 147.15x across 82 trusted points (Rs 19.96-2937.12). NOTE: mixes strengths (graph prices carry no strength), so treat as indicative.

Regulatory risk

1 DRAP alert(s), latest 2025-10-16 incl. recall/safety.

Confidence

Reduced by: no ATC code.

Packaged brief for this lower opportunity?

Molecule page + company profiles + price-room analysis are the pilot package for pharma teams.

See packaged reports All 3868 molecules

Molecule intelligence as of 2026-07-30. Brand/company counts from DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.